Harbin Gloria Pharmaceuticals Co Ltd banner

Harbin Gloria Pharmaceuticals Co Ltd
SZSE:002437

Watchlist Manager
Harbin Gloria Pharmaceuticals Co Ltd Logo
Harbin Gloria Pharmaceuticals Co Ltd
SZSE:002437
Watchlist
Price: 3.42 CNY -1.16% Market Closed
Market Cap: ¥7.6B

Relative Value

The Relative Value of one Harbin Gloria Pharmaceuticals Co Ltd stock under the Base Case scenario is hidden CNY. Compared to the current market price of 3.42 CNY, Harbin Gloria Pharmaceuticals Co Ltd is hidden .

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

Harbin Gloria Pharmaceuticals Co Ltd Relative Value
HIDDEN
Show
Worst Case
Base Case
Best Case

Multiples Across Competitors

Competitors Multiples
Harbin Gloria Pharmaceuticals Co Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
CN
Harbin Gloria Pharmaceuticals Co Ltd
SZSE:002437
7.7B CNY 3.4 26.2 24.4 24.4
US
Eli Lilly and Co
NYSE:LLY
997.2B USD 15.3 48.3 32.5 34.6
US
Johnson & Johnson
NYSE:JNJ
578.6B USD 6.1 21.6 15 18.4
CH
Roche Holding AG
SIX:ROG
281.1B CHF 4.6 30 12.7 14.8
US
Merck & Co Inc
NYSE:MRK
303.5B USD 4.7 16.6 10.4 12.1
CH
Novartis AG
SIX:NOVN
230.9B CHF 5.3 21.2 13.1 16.8
UK
AstraZeneca PLC
LSE:AZN
216.1B GBP 5.2 32.1 15.3 22.4
IE
Endo International PLC
LSE:0Y5F
218B USD 94 -74.6 333.1 835.4
DK
Novo Nordisk A/S
CSE:NOVO B
1.3T DKK 4.2 12.7 9.3 11
US
Pfizer Inc
NYSE:PFE
154.7B USD 2.5 19.9 7.4 9.9
US
Bristol-Myers Squibb Co
NYSE:BMY
125.6B USD 2.6 20.8 7.3 9.6
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
CN
Harbin Gloria Pharmaceuticals Co Ltd
SZSE:002437
Average EV/EBITDA: 43.7
24.4
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
32.5
18%
1.8
US
Johnson & Johnson
NYSE:JNJ
15
2%
7.5
CH
Roche Holding AG
SIX:ROG
12.7
5%
2.5
US
Merck & Co Inc
NYSE:MRK
10.4
7%
1.5
CH
Novartis AG
SIX:NOVN
13.1
9%
1.5
UK
AstraZeneca PLC
LSE:AZN
15.3
10%
1.5
IE
E
Endo International PLC
LSE:0Y5F
333.1
N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
9.3
7%
1.3
US
Pfizer Inc
NYSE:PFE
7.4
-4%
N/A
US
Bristol-Myers Squibb Co
NYSE:BMY
7.3
-9%
N/A